Evaluation of the activity of microparticles containing trans-resveratrol nanoparticles against clinical strains of Helicobacter pylori: in vitro study

• Grant number: 21/11681-5
• Support Opportunities: Scholarships abroad - Research Internship - Doctorate
• Start date: April 04, 2022
• End date: April 03, 2023
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Marlus Chorilli
• Grantee: Larissa Sposito
• Supervisor: Maria Cristina Teixeira Lopes da Costa Pinto Lopes Martins
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Institution abroad: Universidade do Porto (UP), Portugal
• Associated to the scholarship: 19/09597-6 - Gastroretentive microparticles containing trans resveratrol nanoparticles applied to the treatment of Helicobacter pylori infections, BP.DR

Abstract

Helicobacter pylori is a microorganism that is directly related to severe clinical conditions of chronic gastritis, peptic ulcer, and gastric cancer. The virulence factors and the ability of these bacteria to form biofilms increase the resistance to conventional antimicrobials. In this sense, there is a growing interest in the search for new substances, among them of natural origin, as well as new treatment strategies against H. pylori. The use of microparticles containing nanoparticles with gastro retentive character proves to be an interesting strategy for oral administration aiming at the vectorization to the gastric region of active substances, such as trans-resveratrol (RESV), aiming at potential application against H. pylori infections. Thus, the proposed project aims to use microparticles containing RESV nanoparticles already developed in the beneficiary's project in the country against multiresistant clinical strains of H. pylori, the interaction of the delivery system with bacterial cells and its cytotoxicity will also be evaluated in the stomach cell line. Thus, it is expected that the system already developed has antibacterial activity in multiresistant strains in the proposed in vitro experiments, in line with the low toxicity in stomach strains. (AU)